Experts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.
This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.
The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.
Approximate Time to Complete: 30 minutes
Credit Available: Apr. 30, 2019- Apr. 30, 2020
Developed through a partnership between SITC and Medscape.
Original Course Date: April 30, 2019
Approved Credit:
ABIM: 0.50 hours ABIM MOC Part 2 Credits
ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
Nursing experts discuss the emergence of immunotherapy in GI cancers, focusing on the role of biomarkers and the management of irAEs.
This activity is intended for nurses and other healthcare professionals who manage patients with gastrointestinal cancers.
The goal of this activity is to discuss the emerging role of immunotherapy using immune checkpoint inhibitors in patients with gastrointestinal cancers.
Approximate Time to Complete: 30 minutes
Credit Available: Apr. 30, 2019 - Apr. 30, 2020
Developed through a partnership between SITC and Medscape.
This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.
You will learn about:
What chemotherapy is and how it is used to treat advanced bladder cancer
What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
The potential side effects of chemotherapy and checkpoint inhibitors
Why the side effects from chemotherapy and checkpoint inhibitors are different
Questions to ask your doctor
Available beginning: April 26, 2019
Approximate Time to Complete: 30 minutes
Developed through a partnership between SITC and Medscape.
Explore the latest in melanoma care through 2 cases, one in the adjuvant setting and one in the metastatic setting.
This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with melanoma.
Credit Available: Feb. 25, 2019 - Feb. 25, 2020
Approximate Time to Complete: 75 minutes
Developed through a partnership between SITC and Medscape.
Cookies are small pieces of information that are stored by your browser on your computer’s hard drive.
This website uses cookies to enhance the convenience and use of the site, and has placed cookies already.
You can delete or block cookies within your browser settings.
Should you opt to do this, some parts of our site may not work.
By using this site, you agree to our use of cookies.
For more information, including instructions on how to remove the cookies that have been placed,
see our Privacy Policy.
Experts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.
Nursing experts discuss the emergence of immunotherapy in GI cancers, focusing on the role of biomarkers and the management of irAEs.
This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.
Explore the latest in melanoma care through 2 cases, one in the adjuvant setting and one in the metastatic setting.
